Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket-Reference-Cited by-同舟云学术

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket

Published:2016-11 Issue:11 Volume:23 Page:1335-1340
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Forster Michael,Chaikuad Apirat,Bauer Silke M.,Holstein Julia,Robers Matthew B.,Corona Cesear R.,Gehringer Matthias,Pfaffenrot Ellen,Ghoreschi Kamran,Knapp Stefan,Laufer Stefan A.

Funder

AbbVie

Bayer Pharma AG

Boehringer Ingelheim

Canada Foundation for Innovation

Eshelman Institute for Innovation

Genome Canada through Ontario Genomics Institute

Innovative Medicines Initiative

Janssen

gs9:Merck

Novartis Pharma AG

Ontario Ministry of Economic Development and Innovation

Pfizer

São Paulo Research Foundation-FAPESP

Takeda

Wellcome Trust

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry

Reference22 articles.

1. Pyrrolopyrimidines as Janus Kinase Inhibitors. WO Patent 2013/085802;Ahearn,2013

2. A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors;Bauer;Anal. Methods,2014

3. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6;Chrencik;J. Mol. Biol.,2010

4. Discovery of CP-690'550: a potent and selective Janus Kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection;Flanagan;J. Med. Chem.,2010

5. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes;Gehringer;ChemMedChem,2014

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the design of small molecular drugs with acrylamides covalent warheads;Bioorganic & Medicinal Chemistry;2024-10

2. Computational drug repositioning for IL6 triggered JAK3 in rheumatoid arthritis using FDA database;Molecular Diversity;2024-08-14

3. Evaluation of the Efficacy of Tofacitinib, a JAK Inhibitor, in Alleviating Sepsis-Induced Multiple Organ Dysfunction Syndrome;Drug Research;2024-08-12

4. Identification of novel covalent JAK3 inhibitors through consensus scoring virtual screening: integration of common feature pharmacophore and covalent docking;Molecular Diversity;2024-07-15

5. Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update;Journal of Medicinal Chemistry;2024-05-07